Kinnate Biopharma Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Kinnate Biopharma last-minute Real Value cannot be determined due to lack of data. The latest price of Kinnate Biopharma is $0.0. Our model forecasts the value of Kinnate Biopharma from analyzing the firm fundamentals such as Return On Equity of -0.56, current valuation of (25.71 M), and Shares Owned By Insiders of 0.15 % as well as examining its technical indicators and probability of bankruptcy.
Kinnate Biopharma Total Value Analysis
Kinnate Biopharma is now anticipated to have valuation of (25.71 M) with market capitalization of 124.99 M, debt of 3.17 M, and cash on hands of 262.42 M. The negative valuation of Kinnate Biopharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Kinnate Biopharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(25.71 M) | 124.99 M | 3.17 M | 262.42 M |
Kinnate Biopharma Asset Utilization
One of the ways to look at asset utilization of Kinnate is to check how much profit was generated for every dollar of assets it reports. Kinnate Biopharma secures a negative usage of assets of -0.34 %, losing $0.003363 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Kinnate Biopharma shows how discouraging it operates for each dollar spent on its assets.Kinnate Biopharma Ownership Allocation
Kinnate Biopharma maintains a total of 47.17 Million outstanding shares. The majority of Kinnate Biopharma outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kinnate Biopharma to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kinnate Biopharma. Please pay attention to any change in the institutional holdings of Kinnate Biopharma as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Kinnate Biopharma Profitability Analysis
Net Loss for the year was (112.65 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Kinnate Biopharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Kinnate Biopharma and how it compares across the competition.
Kinnate Biopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Kinnate Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 46.6 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |